Compare Global X Uranium ETF (URA) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Uranium ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Global X Uranium ETF trades at $45.03, while State Street SPDR S&P Biotech ETF trades at $159.12. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Global X Uranium ETF nearer its low. Which is the better fit depends on your goals.
| URA | XBI | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Broad Market / Factor |
52-Week High | $61.81 | $164.28 |
52-Week Low | $36.45 | $88.79 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
URA, the Global X Uranium ETF, trades at $45.20, up 1.85% on the day, with a bullish technical signal from moving averages and strong buying pressure indicated by ADX. The ETF benefits from positive sentiment around nuclear energy demand driven by AI power needs and government support, including a recent $17.5 billion U.S. loan commitment for new reactors. However, RSI levels suggest potential overbought conditions near-term.
The outlook for URA is positive due to structural tailwinds in nuclear energy, but risks include ETF expense ratios and uranium price volatility. Investor sentiment is bolstered by index expansions and geopolitical deals, yet the fund lacks traditional valuation metrics as it holds diversified uranium-related equities rather than operating as a single company.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
